[go: up one dir, main page]

WO1999019488A8 - Novel human egf receptors and use thereof - Google Patents

Novel human egf receptors and use thereof

Info

Publication number
WO1999019488A8
WO1999019488A8 PCT/US1998/021828 US9821828W WO9919488A8 WO 1999019488 A8 WO1999019488 A8 WO 1999019488A8 US 9821828 W US9821828 W US 9821828W WO 9919488 A8 WO9919488 A8 WO 9919488A8
Authority
WO
WIPO (PCT)
Prior art keywords
novel human
human egf
egf receptors
growth factor
present
Prior art date
Application number
PCT/US1998/021828
Other languages
French (fr)
Other versions
WO1999019488A9 (en
WO1999019488A1 (en
Inventor
Michael Klagsbrun
Klaus Elenius
Gabriel Corfas
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Priority to AU98053/98A priority Critical patent/AU9805398A/en
Publication of WO1999019488A1 publication Critical patent/WO1999019488A1/en
Publication of WO1999019488A9 publication Critical patent/WO1999019488A9/en
Publication of WO1999019488A8 publication Critical patent/WO1999019488A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates generally to epidermal growth factor receptors. More specifically, the present invention relates to novel isoforms of human epidermal growth factor receptor, particularly HER4/ErbB4, and uses thereof.
PCT/US1998/021828 1997-10-15 1998-10-15 Novel human egf receptors and use thereof WO1999019488A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU98053/98A AU9805398A (en) 1997-10-15 1998-10-15 Novel human egf receptors and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6237397P 1997-10-15 1997-10-15
US60/062,373 1997-10-15

Publications (3)

Publication Number Publication Date
WO1999019488A1 WO1999019488A1 (en) 1999-04-22
WO1999019488A9 WO1999019488A9 (en) 1999-06-03
WO1999019488A8 true WO1999019488A8 (en) 1999-10-14

Family

ID=22042059

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/021828 WO1999019488A1 (en) 1997-10-15 1998-10-15 Novel human egf receptors and use thereof

Country Status (2)

Country Link
AU (1) AU9805398A (en)
WO (1) WO1999019488A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102216331A (en) * 2008-10-17 2011-10-12 霍夫曼-拉罗奇有限公司 Treatment method

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122014028365B8 (en) 1999-06-25 2021-07-06 Genentech Inc manufactured article comprising a first container comprising a composition of humab4d5-8 contained therein and a second container comprising a composition of rhumab 2c4 contained therein
DK2283867T3 (en) 1999-06-25 2014-06-10 Immunogen Inc Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
EP2110138A1 (en) 1999-08-27 2009-10-21 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies
PL357939A1 (en) 2000-04-11 2004-08-09 Genentech, Inc. Multivalent antibodies and uses therefor
KR101135233B1 (en) 2000-05-19 2012-04-12 제넨테크, 인크. Gene Detection Assay for Improving the Likelihood of an Effective Response to an ErbB Antagonist Cancer Therapy
AUPQ841800A0 (en) * 2000-06-28 2000-07-20 Biomolecular Research Institute Limited Truncated egf receptor
US6255111B1 (en) 2000-07-31 2001-07-03 Isis Pharmaceuticals, Inc. Antisense modulation of Her-4 expression
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
CA2490758C (en) 2002-07-15 2014-09-23 Genentech, Inc. Dosage form of recombinant humanized monoclonal antibody 2c4
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
US7939267B2 (en) 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
CA2592177A1 (en) 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
BRPI0606542A8 (en) 2005-02-23 2018-03-20 Genentech Inc methods to increase the time to disease progression (ttp)
KR20150039212A (en) 2007-03-02 2015-04-09 제넨테크, 인크. Predicting response to a her dimerisation inhibitor based on low her3 expression
ES2583377T3 (en) 2007-06-08 2016-09-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
MX2011005382A (en) * 2008-11-25 2011-07-20 Genentech Inc Isoform specific anti-her4 antibodies.
TW201544123A (en) 2009-03-20 2015-12-01 Genentech Inc Anti-HER antibodies
RU2580038C2 (en) 2009-12-04 2016-04-10 Дженентек, Инк. Multispecific antibodies, thereof analogues, compositions and methods
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
HRP20170462T1 (en) 2010-08-20 2017-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
EP2751285B2 (en) 2011-08-31 2020-04-01 Genentech, Inc. Method for sensitivity testing of a tumour for a egfr kinase inhibitor
JP2015500638A (en) 2011-11-30 2015-01-08 ジェネンテック， インコーポレイテッド ERBB3 mutations in cancer
US20130251703A1 (en) 2011-12-05 2013-09-26 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
AU2013240261A1 (en) 2012-03-27 2014-09-18 Genentech, Inc. Diagnosis and treatments relating to HER3 inhibitors
CN107002119A (en) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 Treatment of cancer and the former and associating that HGF is expressed using C MET antagonists
WO2016011167A1 (en) 2014-07-16 2016-01-21 Dana-Farber Cancer Institute, Inc., Et Al Her3 inhibition in low-grade serous ovarian cancers
KR20190140952A (en) 2017-04-24 2019-12-20 제넨테크, 인크. ERBB2 / HER2 mutations in transmembrane and proximal membrane domains

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI971532A7 (en) * 1994-10-14 1997-06-11 Bristol Myers Squibb Co HER4, a human receptor tyrosine kinase, which belongs to the group of dermal growth factor receptors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102216331A (en) * 2008-10-17 2011-10-12 霍夫曼-拉罗奇有限公司 Treatment method

Also Published As

Publication number Publication date
WO1999019488A9 (en) 1999-06-03
WO1999019488A1 (en) 1999-04-22
AU9805398A (en) 1999-05-03

Similar Documents

Publication Publication Date Title
WO1999019488A8 (en) Novel human egf receptors and use thereof
AU1746600A (en) Reduction, elimination, or stimulation of hair growth
IN1998DE01360A (en)
AU7483398A (en) Skin care compositions and method of improving skin appearance
ZA9710098B (en) Halogenopyrimidines.
WO2001078702A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
ZA9711121B (en) Reduction of hair growth.
IL125124A0 (en) Dimeric forms of the protein fapalpha and uses thereof
WO1999029729A3 (en) Antagonists of neuropilin receptor function and use thereof
ZA976348B (en) Reduction of hair growth.
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
AU9319798A (en) Reduction of hair growth
WO2001078703A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
ZA9711328B (en) Reduction of hair growth.
AU2002332923A1 (en) Antisense modulation of fibroblast growth factor receptor 3 expression
BG101787A (en) Aprotinine options having improved properties
AU5486500A (en) Antisense modulation of jun n-terminal kinase kinase-2 expression
AU1903799A (en) Compositions and methods for modulating the activity of fibroblast growth factor
AU7595298A (en) Azolidinediones useful for the treatment of diabetes, dyslipidemia and hy pertension
AU5857298A (en) Medical scissors with coating to reduce wear
AU2002251788A1 (en) Novel compounds and uses thereof
ZA977491B (en) Use of polyhydroxycarboxylamides as EP additives.
AU2436095A (en) Cloning, expression, and uses of human lactoferrin
AU5549296A (en) Extracellular/epidermal growth factor-like protein
FI971532A7 (en) HER4, a human receptor tyrosine kinase, which belongs to the group of dermal growth factor receptors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/14-14/14, DRAWINGS, REPLACED BY NEW PAGES 1/14-14/14; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: CA